For many years, Alzheimer’s treatment focused mainly on managing symptoms after memory problems had already appeared.
The approval of lecanemab in Canada marks an important milestone because it is one of the first medicines designed to slow the disease itself. Even so, specialists caution that patients and families should understand both the opportunities and the limitations before starting therapy.
Specialists writing in the Canadian Medical Association Journal explain that although lecanemab represents scientific progress, its real-world benefits remain modest and the treatment requires careful monitoring.
Lecanemab works differently from older Alzheimer’s medicines. Instead of simply improving communication between nerve cells, it targets amyloid, a protein that accumulates in the brains of many people with Alzheimer’s disease. The medicine helps remove some of these amyloid deposits, with the goal of slowing ongoing damage to brain cells.
Research has shown that patients taking lecanemab experienced slower cognitive decline than those receiving inactive treatment. However, the improvement was relatively small, and researchers are still uncertain how much this translates into better daily functioning, greater independence, or reduced stress for caregivers over many years.
Treatment is also more complex than taking ordinary medication. Before starting therapy, doctors must confirm that the patient has early Alzheimer’s disease and evidence of amyloid in the brain.
This usually requires specialized testing with PET imaging or spinal fluid analysis. Patients then receive regular intravenous infusions and repeated MRI scans throughout treatment.
These scans are necessary because lecanemab may cause brain swelling or tiny brain bleeds while clearing amyloid. Although many cases remain mild, some patients develop neurological symptoms, making close medical supervision essential.
The financial cost is another important issue. Annual treatment costs tens of thousands of Canadian dollars, and the medicine is currently not publicly funded. As a result, access may depend on personal finances or future government funding decisions.
The authors believe there is no single correct answer for every patient. Individuals who strongly value even a small slowing of disease progression may accept the inconvenience, monitoring, possible side effects, and cost. Others may reasonably decide to postpone treatment until additional evidence becomes available or newer therapies emerge.
The discussion also highlights the importance of shared decision-making. Doctors, patients, and family caregivers should openly discuss treatment goals, expectations, risks, quality of life, and practical considerations before making a final decision.
Scientists continue developing new Alzheimer’s therapies, and future medicines may prove more effective or easier to use. Lecanemab therefore represents one important step rather than the final answer to Alzheimer’s disease.
The article was published in the Canadian Medical Association Journal.
The authors present a careful and evidence-based assessment instead of overstating the drug’s benefits. Their message is that scientific progress should be welcomed, but realistic expectations are equally important.
This balanced discussion will help patients understand that treatment decisions depend not only on clinical trial results but also on personal values, financial considerations, and willingness to accept potential risks. As additional studies become available, recommendations may continue to evolve.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: University of Toronto.
